Gain the skills, dexterity and confidence to propel your career into senior management. Whether the goal is to create a standalone solution or fashion part of a complex talent development initiative, ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

When we go to the supermarket, we’re confronted with a vast array of foods — packaged, unpackaged, natural, organic, nonorganic, foods with claims of being nutritious or sustainably farmed or endorsed ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

Our CEPH-accredited public health programs prepare undergraduate, masters, and doctoral students using a curriculum focused on problem solving and real-life practical experiences. Learn more about ...

We might earn a commission if you make a purchase through one of the links. The McClatchy Commerce Content team, which is independent from our newsroom, oversees this content. This article has ...